Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Phytocannabinoids, particularly cannabidiol (CBD), have garnered scientific interest as potential adjuncts in the management of addiction. Animal studies and early-stage human trials suggest that certain phytocannabinoids may modulate neural circuits involved in drug-seeking behavior, stress response, and reward. For instance, CBD has demonstrated the ability to reduce cue-induced cravings and anxiety in individuals with heroin use disorder, as shown in a small randomized clinical trial (Hurd et al., 2019). Other studies have explored the role of cannabinoids in mitigating withdrawal symptoms and relapse in nicotine, alcohol, and opioid addiction models. The proposed mechanisms involve modulation of the endocannabinoid system, particularly CB1 and CB2 receptors, which influence dopamine signaling and emotional regulation.

However, the evidence base remains limited and is not yet robust enough to support widespread clinical use. Most available research is preclinical or involves small sample sizes, short durations, and varied formulations/doses of phytocannabinoids. There are also concerns regarding the potential for abuse with certain cannabinoids (notably THC) and possible drug interactions. Despite anecdotal reports and some traditional use (e.g., cannabis for opium withdrawal in 19th-century medicine), the primary justification for phytocannabinoids in addiction management is grounded in recent scientific exploration rather than longstanding tradition. More large-scale, controlled human studies are required to clarify efficacy, safety, and optimal protocols.

More about phytocannabinoids
More about Addictions (general remedies for)

Other ingredients used for Addictions (general remedies for)

Other health conditions supported by phytocannabinoids

Products containing phytocannabinoids